Cyient Share Buyback: Last Chance to Buy Before June 17 Record Date

Engineering and technology services major Cyient is moving forward with its ₹720 crore share buyback program, offering investors a chance to exit at a significant premium. Shareholders looking to participate in this corporate action must ensure their holdings are secured before the upcoming record date to remain eligible.

Critical Deadlines for Buyback Eligibility

For investors aiming to tender their shares, timing is everything. Cyient has officially fixed June 17 (Wednesday) as the record date for the buyback. Under SEBI’s T+1 settlement norms, shares must be credited to an investor's demat account by the record date to qualify.

Consequently, June 16 (Tuesday) serves as the final deadline for purchasing Cyient shares. Any investor who completes their purchase by this date will ensure their holdings are reflected in their accounts by Wednesday, making them eligible to participate in the repurchase process.

Understanding the ₹720 Crore Buyback Terms

This marks Cyient's first share buyback since 2019. The company has announced plans to repurchase up to 64 lakh shares at a fixed price of ₹1,125 per share. This offer represents an attractive premium of more than 25% over the stock's previous closing price.

While the shareholders have officially approved the buyback, the company is yet to announce the specific entitlement ratio. Typically, such buybacks are executed by companies to utilize surplus cash, enhance shareholder value, or increase promoter holdings.

Stock Performance and Market Outlook

Despite the attractive buyback price, Cyient's recent market performance has been under pressure. The stock was trading around ₹886 on Tuesday morning, marking a slight decline. While the stock has seen a 2% gain over the last week, it remains down more than 20% in 2026. Looking at longer horizons, the shares have fallen 33% over the last year and 41% over three years, though they maintain a 5% gain over a five-year period.

The company currently holds a market capitalization exceeding ₹9,853 crore.

Analyst Views: Emkay Maintains 'Reduce' Rating

자사주 매입 기회에도 불구하고 증권사들은 신중한 태도를 유지하고 있습니다. Emkay는 Cyient 주식에 대해 '축소(Reduce)' 의견을 유지했습니다. 해당 증권사는 목표 주가를 ₹850에서 ₹900로 상향 조정했으나, 이는 최근 종가인 ₹897 대비 상승 여력이 미미함을 의미합니다.

해당 증권사는 이러한 신중한 입장의 원인으로 거시 경제적 역풍에 따른 2026 회계연도(FY26)의 성장 둔화를 꼽았습니다. 엔지니어링 연구개발(ER&D) 지출은 견조한 수준을 유지하고 있으나, 매출 약화와 글로벌 공급망 문제로 인한 DLM 재고 회전 일수 증가와 같은 과제들이 향후 전망에 영향을 미쳤습니다. 하지만 경영진은 2027 회계연도(FY27)에 더욱 강력하고 수익성 있는 성장을 달성할 수 있을 것으로 낙관하고 있습니다.

핵심 요약